{"id":745470,"date":"2017-10-18T05:55:00","date_gmt":"2017-10-18T05:55:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/u-s-fda-accepts-regulatory-submission-for-lynparza-olaparib-in-metastatic-breast-cancer-and-grants-priority-review\/"},"modified":"2025-11-07T01:26:11","modified_gmt":"2025-11-07T06:26:11","slug":"u-s-fda-accepts-regulatory-submission-for-lynparza-olaparib-in-metastatic-breast-cancer-and-grants-priority-review","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/u-s-fda-accepts-regulatory-submission-for-lynparza-olaparib-in-metastatic-breast-cancer-and-grants-priority-review\/","title":{"rendered":"U.S. FDA Accepts Regulatory Submission for LYNPARZA\u00ae (olaparib) in Metastatic Breast Cancer and Grants Priority Review"},"content":{"rendered":"<p class=\"bwalignc\">       LYNPARZA Has the Potential to Offer a New Treatment Option for        Patients with Germline BRCA-Mutated, HER2-Negative Metastatic Breast        Cancer     <\/p>\n<p class=\"bwalignc\">       Regulatory Submission Acceptance Is the First for a PARP Inhibitor        Beyond Ovarian Cancer     <\/p>\n<p>\n      AstraZeneca and Merck (NYSE:MRK),&nbsp;known as MSD outside the United States<br \/>\n      and Canada, today announced that the U.S. Food and Drug Administration<br \/>\n      (FDA) has accepted and granted priority review for a supplemental New<br \/>\n      Drug Application (sNDA) for the use of LYNPARZA<sup>\u00ae <\/sup>(olaparib)<br \/>\n      tablets in patients with germline <i>BRCA<\/i>-mutated (<i>gBRCA<\/i>),<br \/>\n      HER2-negative metastatic breast cancer (MBC) who have been previously<br \/>\n      treated with chemotherapy either in the neoadjuvant, adjuvant or<br \/>\n      metastatic settings. A Prescription Drug User Fee Act (PDUFA) date is<br \/>\n      set for the first quarter of 2018.\n    <\/p>\n<p>\n      This is the first submission for a poly ADP-ribose polymerase (PARP)<br \/>\n      inhibitor outside ovarian cancer and the third indication submission for<br \/>\n      LYNPARZA<i> <\/i>in the U.S. The sNDA is based on the positive results<br \/>\n      from the phase 3 OlympiAD trial published in the <i>New England Journal<br \/>\n      of Medicine<\/i>.\n    <\/p>\n<p>\n      LYNPARZA<i> <\/i>was first approved under the FDA\u2019s Accelerated Approval<br \/>\n      program in December 2014, as a capsule formulation, making it the first<br \/>\n      PARP inhibitor ever approved. Since then, more than 3,000 advanced<br \/>\n      ovarian cancer patients have been treated with LYNPARZA<i>. <\/i>LYNPARZA<br \/>\n      tablets are currently being tested in a range of tumor types, including<br \/>\n      breast, prostate and pancreatic cancers.\n    <\/p>\n<p>\n      LYNPARZA tablets are currently approved in the U.S. as a maintenance<br \/>\n      treatment for adult patients with recurrent, epithelial ovarian,<br \/>\n      fallopian tube or primary peritoneal cancer who are in a complete or<br \/>\n      partial response to platinum-based chemotherapy, regardless of <i>BRCA <\/i>status.<sup><br \/>\n      <\/sup>The medicine is also indicated for use in adult patients with<br \/>\n      deleterious or suspected deleterious <i>gBRCA<\/i>-mutated advanced<br \/>\n      ovarian cancer, who have been treated with three or more prior lines of<br \/>\n      chemotherapy; patients for this indication are selected for therapy<br \/>\n      based on an FDA-approved companion diagnostic.\n    <\/p>\n<p>\n      <b>IMPORTANT SAFETY INFORMATION<\/b>\n    <\/p>\n<p>\n      <b>DOSING AND ADMINISTRATION<\/b>\n    <\/p>\n<p>\n      To avoid substitution errors and overdose, <b>do not substitute LYNPARZA <\/b>(olaparib)<br \/>\n      <b>tablets with LYNPARZA capsules <\/b>on a milligram-to-milligram basis<br \/>\n      due to differences in the dosing and bioavailability of each<br \/>\n      formulation. Recommended tablet dose is 300 mg, taken orally twice<br \/>\n      daily, with or without food. Continue treatment until disease<br \/>\n      progression or unacceptable toxicity. For adverse reactions, consider<br \/>\n      dose interruption or dose reduction.\n    <\/p>\n<p>\n      <b>WARNINGS AND PRECAUTIONS<\/b>\n    <\/p>\n<p>\n      There are no contraindications for LYNPARZA.\n    <\/p>\n<p>\n      <b>Myelodysplastic Syndrome\/Acute Myeloid Leukemia (MDS\/AML):&nbsp;<\/b>Occurred<br \/>\n      in &lt;1.5% of patients exposed to LYNPARZA monotherapy, and the majority<br \/>\n      of events had a fatal outcome. The duration of therapy in patients who<br \/>\n      developed secondary MDS\/AML varied from &lt;6 months to &gt;2 years. All of<br \/>\n      these patients had previous chemotherapy with platinum agents and\/or<br \/>\n      other DNA-damaging agents, including radiotherapy, and some of these<br \/>\n      patients also had a history of previous cancer or bone marrow dysplasia.\n    <\/p>\n<p>\n      Do not start LYNPARZA until patients have recovered from hematological<br \/>\n      toxicity caused by previous chemotherapy (\u2264Grade 1). Monitor complete<br \/>\n      blood counts for cytopenia at baseline and monthly thereafter for<br \/>\n      clinically significant changes during treatment. For prolonged<br \/>\n      hematological toxicities, interrupt LYNPARZA and monitor blood counts<br \/>\n      weekly until recovery. If the levels have not recovered to Grade 1 or<br \/>\n      less after 4 weeks, refer the patient to a hematologist for further<br \/>\n      investigations, including bone marrow analysis and blood sample for<br \/>\n      cytogenetics. Discontinue LYNPARZA if MDS\/AML is confirmed.\n    <\/p>\n<p>\n      <b>Pneumonitis:<\/b>&nbsp;Occurred in &lt;1% of patients exposed to LYNPARZA, and<br \/>\n      some cases were fatal. If patients present with new or worsening<br \/>\n      respiratory symptoms such as dyspnea, cough, and fever, or a<br \/>\n      radiological abnormality occurs, interrupt treatment with LYNPARZA and<br \/>\n      initiate prompt investigation. Discontinue LYNPARZA (olaparib) if<br \/>\n      pneumonitis is confirmed and treat patient appropriately.\n    <\/p>\n<p>\n      <b>Embryo-Fetal Toxicity:<\/b>&nbsp;Based on its mechanism of action and<br \/>\n      findings in animals, LYNPARZA can cause fetal harm. A pregnancy test is<br \/>\n      recommended for females of reproductive potential prior to initiating<br \/>\n      treatment. Advise females of reproductive potential of the potential<br \/>\n      risk to a fetus and to use effective contraception during treatment and<br \/>\n      for 6 months after receiving the final dose.\n    <\/p>\n<p>\n      <b>ADVERSE REACTIONS\u2014Maintenance Setting<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226520% of patients in<br \/>\n      clinical trials of LYNPARZA in the <b>maintenance setting&nbsp;<\/b>for&nbsp;<b>SOLO-2<\/b>:&nbsp;nausea<br \/>\n      (76%), fatigue (including asthenia) (66%), anemia (44%), vomiting (37%),<br \/>\n      nasopharyngitis\/upper respiratory tract infection (URI)\/influenza (36%),<br \/>\n      diarrhea (33%), arthralgia\/myalgia (30%), dysgeusia (27%), headache<br \/>\n      (26%), decreased appetite (22%), and stomatitis (20%).\n    <\/p>\n<p>\n      <b>Study 19:<\/b> nausea (71%), fatigue (including asthenia) (63%),<br \/>\n      vomiting (35%), diarrhea (28%), anemia (23%), respiratory tract<br \/>\n      infection (22%), constipation (22%), headache (21%), and decreased<br \/>\n      appetite (21%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in<br \/>\n      clinical trials of LYNPARZA in the&nbsp;<b>maintenance setting<br \/>\n      (SOLO-2\/Study 19<\/b>) were: increase in mean corpuscular volume<br \/>\n      (89%\/82%), decrease in hemoglobin (83%\/82%), decrease in leukocytes<br \/>\n      (69%\/58%), decrease in lymphocytes (67%\/52%), decrease in absolute<br \/>\n      neutrophil count (51%\/47%), increase in serum creatinine (44%\/45%), and<br \/>\n      decrease in platelets (42%\/36%).\n    <\/p>\n<p>\n      <b>ADVERSE REACTIONS\u2014Advanced g<i>BRCA<\/i>m ovarian cancer<\/b>\n    <\/p>\n<p>\n      Most common adverse reactions (Grades 1-4) in \u226520% of patients in<br \/>\n      clinical trials of LYNPARZA for <b>advanced g<i>BRCA<\/i>m ovarian cancer<br \/>\n      after 3 or more lines of chemotherapy<\/b> (pooled from 6 studies) were:<br \/>\n      fatigue (including asthenia) (66%), nausea (64%), vomiting (43%), anemia<br \/>\n      (34%), diarrhea (31%), nasopharyngitis\/upper respiratory tract infection<br \/>\n      (URI) (26%), dyspepsia (25%), myalgia (22%), decreased appetite (22%),<br \/>\n      and arthralgia\/musculoskeletal pain (21%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in<br \/>\n      clinical trials of LYNPARZA for <b>advanced g<i>BRCA<\/i>m ovarian cancer<br \/>\n      after 3 or more lines of chemotherapy<\/b> (pooled from 6 studies) were:<br \/>\n      decrease in hemoglobin (90%), increase in mean corpuscular volume (57%),<br \/>\n      decrease in lymphocytes (56%), increase in serum creatinine (30%),<br \/>\n      decrease in platelets (30%), and decrease in absolute neutrophil count<br \/>\n      (25%).\n    <\/p>\n<p>\n      <b>DRUG INTERACTIONS<\/b>\n    <\/p>\n<p>\n      <b>Anticancer Agents:<\/b>&nbsp;Clinical studies of LYNPARZA (olaparib) in<br \/>\n      combination with other myelosuppressive anticancer agents, including<br \/>\n      DNA-damaging agents, indicate a potentiation and prolongation of<br \/>\n      myelosuppressive toxicity.\n    <\/p>\n<p>\n      <b>CYP3A Inhibitors:<\/b>&nbsp;Avoid concomitant use of strong or moderate<br \/>\n      CYP3A inhibitors. If a strong or moderate CYP3A inhibitor must<br \/>\n      be&nbsp;co-administered, reduce the dose of LYNPARZA. Advise patients to<br \/>\n      avoid grapefruit, grapefruit juice, Seville oranges, and Seville orange<br \/>\n      juice during LYNPARZA treatment.\n    <\/p>\n<p>\n      <b>CYP3A Inducers:<\/b>&nbsp;Avoid concomitant use of strong or moderate CYP3A<br \/>\n      inducers when using LYNPARZA. If a moderate inducer cannot be avoided,<br \/>\n      be aware of a potential for decreased efficacy of LYNPARZA.\n    <\/p>\n<p>\n      <b>USE IN SPECIFIC POPULATIONS<\/b>\n    <\/p>\n<p>\n      <b>Pediatric Use:<\/b> The safety and efficacy of LYNPARZA have not been<br \/>\n      established in pediatric patients.\n    <\/p>\n<p>\n      <b>Lactation:<\/b>&nbsp;No data are available regarding the presence of<br \/>\n      olaparib in human milk, the effects on the breastfed infant, or the<br \/>\n      effects on milk production. Because of the potential for serious adverse<br \/>\n      reactions in the breastfed infant, advise a lactating woman not to<br \/>\n      breastfeed during treatment with LYNPARZA and for 1 month after<br \/>\n      receiving the final dose.\n    <\/p>\n<p>\n      <b>Hepatic Impairment:<\/b>&nbsp;No adjustment to the starting dose is<br \/>\n      required in patients with mild hepatic impairment (Child-Pugh<br \/>\n      classification A). There are no data in patients with moderate or severe<br \/>\n      hepatic impairment.\n    <\/p>\n<p>\n      <b>Renal Impairment:<\/b>&nbsp;No adjustment to the starting dose is necessary<br \/>\n      in patients with mild renal impairment&nbsp;(CLcr 51-80 mL\/min).&nbsp;In patients<br \/>\n      with moderate renal impairment&nbsp;(CLcr 31-50 mL\/min),&nbsp;reduce the dose to<br \/>\n      200 mg twice daily. There are no data in patients with severe renal<br \/>\n      impairment or&nbsp;end-stage&nbsp;renal disease&nbsp;(CLcr \u226430 mL\/min).\n    <\/p>\n<p>\n      <b>Please see complete&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.azpicentral.com%2Fpi.html%3Fproduct%3Dlynparza_tb%26country%3Dus%26popup%3Dno&amp;esheet=51700916&amp;newsitemid=20171018005442&amp;lan=en-US&amp;anchor=Prescribing+Information&amp;index=1&amp;md5=b7fad4b5a1ca35b571cc50c16a9c6a0f\" rel=\"nofollow\"><br \/>\n<b>Prescribing<br \/>\n      Information<\/b><br \/>\n<\/a><br \/>\n<b>, including Patient Information (Medication Guide)<\/b>\n    <\/p>\n<p>\n      <b>About OlympiAD<\/b>\n    <\/p>\n<p>\n      OlympiAD is a randomized, open-label, multicenter phase 3 trial<br \/>\n      assessing the efficacy and safety of LYNPARZA (olaparib)<b> <\/b>tablets<br \/>\n      (300mg twice daily) compared to \u2018physician\u2019s choice\u2019 chemotherapy<br \/>\n      (capecitabine, vinorelbine, eribulin) in 302 patients with HER2-negative<br \/>\n      metastatic breast cancer with germline <i>BRCA<\/i>1 or <i>BRCA<\/i>2<br \/>\n      mutations, which are predicted or suspected to be deleterious. The<br \/>\n      international trial was conducted in 19 countries from across Europe,<br \/>\n      Asia, North America and South America.\n    <\/p>\n<p>\n      <b>About LYNPARZA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (olaparib)<\/b>\n    <\/p>\n<p>\n      LYNPARZA was the first FDA-approved oral poly ADP-ribose polymerase<br \/>\n      (PARP) inhibitor that may exploit tumor DNA damage response (DDR)<br \/>\n      pathway deficiencies to potentially kill cancer cells.<sup> <\/sup>Specifically,<br \/>\n      <i>in vitro<\/i> studies have shown that olaparib-induced cytotoxicity<br \/>\n      may involve inhibition of PARP enzymatic activity and increased<br \/>\n      formation of PARP-DNA complexes, resulting in DNA damage and cancer cell<br \/>\n      death.\n    <\/p>\n<p>\n      LYNPARZA is the foundation of AstraZeneca\u2019s industry-leading portfolio<br \/>\n      of compounds targeting DDR mechanisms in cancer cells.\n    <\/p>\n<p>\n      <b>About Metastatic Breast Cancer<\/b>\n    <\/p>\n<p>\n      Approximately one in eight women are diagnosed with breast cancer in the<br \/>\n      U.S.<sup> <\/sup>Of these patients, approximately one-third are either<br \/>\n      diagnosed with or progress to the metastatic stage of the disease.<br \/>\n      Despite treatment options increasing during the past three decades,<br \/>\n      there is currently no cure for patients diagnosed with metastatic breast<br \/>\n      cancer. Thus, the primary aim of treatment is to slow progression of the<br \/>\n      disease for as long as possible, improving or at least maintaining, a<br \/>\n      patient\u2019s quality of life.\n    <\/p>\n<p>\n      <b>About Germline <i>BRCA<\/i> Mutations<\/b>\n    <\/p>\n<p>\n      <i>BRCA<\/i>1 and <i>BRCA<\/i>2 are human genes that produce proteins<br \/>\n      responsible for repairing damaged DNA and play an important role<br \/>\n      maintaining the genetic stability of cells. When either of these genes<br \/>\n      is mutated, or altered, such that its protein product either is not made<br \/>\n      or does not function correctly, DNA damage may not be repaired properly.<br \/>\n      As a result, cells are more likely to develop additional genetic<br \/>\n      alterations that can lead to cancer.\n    <\/p>\n<p>\n      <b>About the AstraZeneca and Merck Strategic Oncology Collaboration<\/b>\n    <\/p>\n<p>\n      On July 27, 2017, AstraZeneca and Merck &amp; Co., Inc., announced a global<br \/>\n      strategic oncology collaboration to co-develop and co-commercialize<br \/>\n      AstraZeneca\u2019s LYNPARZA (olaparib), the world\u2019s first and leading PARP<br \/>\n      inhibitor, and potential new medicine selumetinib, a MEK inhibitor, for<br \/>\n      multiple cancer types. The collaboration is based on increasing evidence<br \/>\n      that PARP and MEK inhibitors can be combined with PD-L1\/PD-1 inhibitors<br \/>\n      for a range of tumor types. Working together, the companies will jointly<br \/>\n      develop LYNPARZA and selumetinib in combination with other potential new<br \/>\n      medicines and as a monotherapy. Independently, the companies will<br \/>\n      develop LYNPARZA and selumetinib in combination with their respective<br \/>\n      PD-L1 and PD-1 medicines.\n    <\/p>\n<p>\n      <b>Merck\u2019s Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, helping people<br \/>\n      fight cancer is our passion and supporting accessibility to our cancer<br \/>\n      medicines is our commitment. Our focus is on pursuing research in<br \/>\n      immuno-oncology and we are accelerating every step in the journey \u2013 from<br \/>\n      lab to clinic \u2013 to potentially bring new hope to people with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program evaluating our anti-PD-1 therapy across more than 30<br \/>\n      tumor types. We also continue to strengthen our immuno-oncology<br \/>\n      portfolio through strategic acquisitions and are prioritizing the<br \/>\n      development of several promising immunotherapeutic candidates with the<br \/>\n      potential to improve the treatment of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51700916&amp;newsitemid=20171018005442&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=2&amp;md5=e2413d47247dd3c70e30cd085e8c321b\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=51700916&amp;newsitemid=20171018005442&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=3&amp;md5=b036e1626d64b7d6dfb79da1ae2d323a\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a>&nbsp;and&nbsp;connect<br \/>\n      with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Ftwitter.com%2Fmerck&amp;esheet=51700916&amp;newsitemid=20171018005442&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=898dda55c3dedc0d18bfef81d9eff044\" rel=\"nofollow\">Twitter<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2Fmerckinvents&amp;esheet=51700916&amp;newsitemid=20171018005442&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=cecaf4268a269f814ccd628d7cf71347\" rel=\"nofollow\">Facebook<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.instagram.com%2Fmerck&amp;esheet=51700916&amp;newsitemid=20171018005442&amp;lan=en-US&amp;anchor=Instagram&amp;index=6&amp;md5=f95df01ee50719d714360ca33f7314f3\" rel=\"nofollow\">Instagram<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2Fuser%2FMerck&amp;esheet=51700916&amp;newsitemid=20171018005442&amp;lan=en-US&amp;anchor=YouTube&amp;index=7&amp;md5=4a689f31d60b74226bcfcf4758c40856\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51700916&amp;newsitemid=20171018005442&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=8&amp;md5=abfd0fb0e2eaf8ffae0581a7175b5597\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2016 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51700916&amp;newsitemid=20171018005442&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=9&amp;md5=977f0a16a9a7f6f08ff0d307f28411ee\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20171018005442r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Courtney        Ronaldo, 908-740-6132<br \/>or<br \/>Investors:<br \/>Teri Loxam,        908-740-1986<br \/>or<br \/>Amy Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>LYNPARZA Has the Potential to Offer a New Treatment Option for Patients with Germline BRCA-Mutated, HER2-Negative Metastatic Breast Cancer Regulatory Submission Acceptance Is the First for a PARP Inhibitor Beyond Ovarian Cancer AstraZeneca and Merck (NYSE:MRK),&nbsp;known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a supplemental New Drug Application (sNDA) for the use of LYNPARZA \u00ae (olaparib) tablets in patients with germline BRCA -mutated ( gBRCA ), HER2-negative metastatic breast cancer (MBC) who have been previously treated with chemotherapy either in the neoadjuvant, adjuvant or metastatic settings. A Prescription Drug User Fee Act (PDUFA) date is set for the first quarter of 2018. This is the first submission for a poly ADP-ribose polymerase (PARP) inhibitor outside ovarian cancer and the third indication submission for LYNPARZA in the U.S. The sNDA is based on the<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,55,289],"class_list":["post-745470","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>U.S. FDA Accepts Regulatory Submission for LYNPARZA\u00ae (olaparib) in Metastatic Breast Cancer and Grants Priority Review - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/u-s-fda-accepts-regulatory-submission-for-lynparza-olaparib-in-metastatic-breast-cancer-and-grants-priority-review\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"U.S. FDA Accepts Regulatory Submission for LYNPARZA\u00ae (olaparib) in Metastatic Breast Cancer and Grants Priority Review - Merck.com\" \/>\n<meta property=\"og:description\" content=\"LYNPARZA Has the Potential to Offer a New Treatment Option for Patients with Germline BRCA-Mutated, HER2-Negative Metastatic Breast Cancer Regulatory Submission Acceptance Is the First for a PARP Inhibitor Beyond Ovarian Cancer AstraZeneca and Merck (NYSE:MRK),&nbsp;known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a supplemental New Drug Application (sNDA) for the use of LYNPARZA \u00ae (olaparib) tablets in patients with germline BRCA -mutated ( gBRCA ), HER2-negative metastatic breast cancer (MBC) who have been previously treated with chemotherapy either in the neoadjuvant, adjuvant or metastatic settings. A Prescription Drug User Fee Act (PDUFA) date is set for the first quarter of 2018. This is the first submission for a poly ADP-ribose polymerase (PARP) inhibitor outside ovarian cancer and the third indication submission for LYNPARZA in the U.S. The sNDA is based on the\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/u-s-fda-accepts-regulatory-submission-for-lynparza-olaparib-in-metastatic-breast-cancer-and-grants-priority-review\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/u-s-fda-accepts-regulatory-submission-for-lynparza-olaparib-in-metastatic-breast-cancer-and-grants-priority-review\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/u-s-fda-accepts-regulatory-submission-for-lynparza-olaparib-in-metastatic-breast-cancer-and-grants-priority-review\\\/\",\"name\":\"U.S. FDA Accepts Regulatory Submission for LYNPARZA\u00ae (olaparib) in Metastatic Breast Cancer and Grants Priority Review - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2017-10-18T05:55:00+00:00\",\"dateModified\":\"2025-11-07T06:26:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/u-s-fda-accepts-regulatory-submission-for-lynparza-olaparib-in-metastatic-breast-cancer-and-grants-priority-review\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/u-s-fda-accepts-regulatory-submission-for-lynparza-olaparib-in-metastatic-breast-cancer-and-grants-priority-review\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/u-s-fda-accepts-regulatory-submission-for-lynparza-olaparib-in-metastatic-breast-cancer-and-grants-priority-review\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"U.S. FDA Accepts Regulatory Submission for LYNPARZA\u00ae (olaparib) in Metastatic Breast Cancer and Grants Priority Review\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"U.S. FDA Accepts Regulatory Submission for LYNPARZA\u00ae (olaparib) in Metastatic Breast Cancer and Grants Priority Review - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/u-s-fda-accepts-regulatory-submission-for-lynparza-olaparib-in-metastatic-breast-cancer-and-grants-priority-review\/","og_locale":"en_US","og_type":"article","og_title":"U.S. FDA Accepts Regulatory Submission for LYNPARZA\u00ae (olaparib) in Metastatic Breast Cancer and Grants Priority Review - Merck.com","og_description":"LYNPARZA Has the Potential to Offer a New Treatment Option for Patients with Germline BRCA-Mutated, HER2-Negative Metastatic Breast Cancer Regulatory Submission Acceptance Is the First for a PARP Inhibitor Beyond Ovarian Cancer AstraZeneca and Merck (NYSE:MRK),&nbsp;known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a supplemental New Drug Application (sNDA) for the use of LYNPARZA \u00ae (olaparib) tablets in patients with germline BRCA -mutated ( gBRCA ), HER2-negative metastatic breast cancer (MBC) who have been previously treated with chemotherapy either in the neoadjuvant, adjuvant or metastatic settings. A Prescription Drug User Fee Act (PDUFA) date is set for the first quarter of 2018. This is the first submission for a poly ADP-ribose polymerase (PARP) inhibitor outside ovarian cancer and the third indication submission for LYNPARZA in the U.S. The sNDA is based on the","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/u-s-fda-accepts-regulatory-submission-for-lynparza-olaparib-in-metastatic-breast-cancer-and-grants-priority-review\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:11+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/u-s-fda-accepts-regulatory-submission-for-lynparza-olaparib-in-metastatic-breast-cancer-and-grants-priority-review\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/u-s-fda-accepts-regulatory-submission-for-lynparza-olaparib-in-metastatic-breast-cancer-and-grants-priority-review\/","name":"U.S. FDA Accepts Regulatory Submission for LYNPARZA\u00ae (olaparib) in Metastatic Breast Cancer and Grants Priority Review - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2017-10-18T05:55:00+00:00","dateModified":"2025-11-07T06:26:11+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/u-s-fda-accepts-regulatory-submission-for-lynparza-olaparib-in-metastatic-breast-cancer-and-grants-priority-review\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/u-s-fda-accepts-regulatory-submission-for-lynparza-olaparib-in-metastatic-breast-cancer-and-grants-priority-review\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/u-s-fda-accepts-regulatory-submission-for-lynparza-olaparib-in-metastatic-breast-cancer-and-grants-priority-review\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"U.S. FDA Accepts Regulatory Submission for LYNPARZA\u00ae (olaparib) in Metastatic Breast Cancer and Grants Priority Review"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"1d85c7f1-3ec6-4fb4-a1df-724592f61c55","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/US-FDA-Accepts-Regulatory-Submission-for-LYNPARZA-olaparib-in-Metastatic-Breast-Cancer-and-Grants-Priority-Review-2017.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745470","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745470\/revisions"}],"predecessor-version":[{"id":3674838,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745470\/revisions\/3674838"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745470"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745470"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}